Simian-human immunodeficiency virus (SHIV) infection in the macaque is a model of HIV pathogenesis. KB9, a molecular clone of SHIV 89.6P, induced rapid and profound CD4 ϩ T cell loss in rhesus monkeys, followed by partial recovery in some. We describe another clinical outcome after intravenous SHIV-KB9 inoculation in two of six infected rhesus macaques: lack of signs of immunodeficiency with sustained CD4 ϩ T cell counts, despite virus load levels similar to those of the animals with CD4 ϩ lymphocyte decline. To dissect the role of host factors in determining pathogenicity of this viral clone, humoral and cellular immune responses were studied. Differences in CD8 ϩ T cell effector responses and activation profiles and in thymic output, but not in specific antibody production, were observed in animals with different disease outcomes during acute infection. Thymic involvement may thus be a critical factor in determining disease progression. © 2002 Elsevier Science (USA) 
INTRODUCTION
Simian immunodeficiency virus (SIV) infection of macaques is a useful model of pathogenesis of lentivirus infection. However, a major limitation of the macaque model is that SIV is antigenically distinct from human immunodeficiency virus (HIV) types 1 and 2 and is not an appropriate challenge virus for human vaccine and antiviral compound studies. The construction of SHIV chimeras, where the env, tat, and rev genes of SIV were replaced by those of HIV-1, was a breakthrough in this direction. One such virus, SHIV-KB9, originally observed to cause a uniquely rapid and profound CD4 ϩ cell loss and AIDS-like immunodeficiency disease, was described (Karlsson et al., 1997; Reimann et al., 1996) . Such rapid lymphodepletion may be due to thymic disruption induced by the virus (Ilda et al., 2000) . However, in subsequent studies, this virus was found to display variability in disease progression patterns (Reimann et al., 1999) . Infection resulted in rapid and profound CD4 ϩ T cell loss in 5 of 15 animals infected, without antibody production against viral antigens, and a substantial but less profound and partially reversible CD4 ϩ T cell depletion with rapid seroconversion in the other two-thirds. The level of plasma viremia did not differ between SHIV-KB9-infected animals exhibiting these different outcomes (Reimann et al., 1999) . We describe herein yet another outcome of SHIV-KB9 infection in two of six rhesus macaques: A pattern of nonprogressive infection, characterized by persistence of normal CD4 ϩ cell counts and rapid antibody seroconversion, without any clinical or laboratory evidence of immunodeficiency, despite virus load measurements comparable with those of the animals which did exhibit CD4 ϩ lymphodepletion. In this study, we further characterize cellular and humoral immunologic responses and thymic output in the animals exhibiting the contrasting patterns of disease.
RESULTS

Clinical and immunological course after SHIV-KB9 infection
Consistent with previous reports, we noted variability in the clinical outcomes of monkeys infected with SHIV-KB9. However, we further noticed that a group of animals did not show any clinical or laboratory sign of immunodeficiency, despite comparable levels of plasma viremia. Two of the six animals (group A, RBJ-5, RAQ-5) displayed a pattern of rapid and profound CD4 ϩ lymphocyte depletion, reaching a nadir of Ͻ50 CD4 ϩ cells/cu mm within 2 weeks postinfection without recovery ( Fig. 1) and died 2 and 8 months after infection, respectively, due to diarrhea, weight loss, and debilitation. Both animals were started on PMPA therapy; RBJ-5 at 6 weeks and RAQ-5 at 14 weeks after inoculation. In both of these instances a modest CD4 ϩ T cell increase was observed. At autopsy they both exhibited severe thymic involution. Two other animals (group B, RHR-5, RQI-5) exhibited a pattern of rapid but less pronounced CD4 ϩ lymphocyte loss to a nadir of approximately 150 CD4 ϩ cells/cu mm, but partially recovered their CD4 ϩ lymphocytes ( Fig. 1) and have remained alive 20 months postinfection. In one of these (RQI-5), treatment with PMPA was started at 8 weeks after inoculation, after which a CD4 ϩ increase was observed; however, the medication was discontinued 4 weeks later with sustained increase in the CD4 ϩ T cell count after its discontinuation. The two remaining animals (group C, RDO-5, RAP-5) did not show any signs or symptoms of disease and their CD4 ϩ counts remained at preinfection levels (Fig. 1) .
The CD8 ϩ lymphocytes displayed a transient decrease followed by a more sustained increase in groups A and B and were preserved until late disease. The two animals of group C showed only transient modest CD8 ϩ T cell count increases that soon stabilized to preinfection levels. Several activation markers on the CD8 ϩ lymphocytes were studied. There was an increase in the proportion of activated CD8 ϩ lymphocytes following infection, as demonstrated by expression of HLA-DR and CD69 markers (Fig. 2) . The animals in which the CD4 ϩ counts were not affected (group C) showed the smallest increases of CD8 ϩ lymphocyte activation marker expression. Much greater increases were observed in the animals that demonstrated CD4 ϩ depletion; those with partial CD4 ϩ T cell recovery (group B) had the most pronounced activation levels of CD8 ϩ lymphocytes (Fig. 2) . By 14 weeks after inoculation, HLA-DR expression on CD8 ϩ cells had waned to preactivation levels in all groups. At the acute infection stage there was an in-crease in the percentage and absolute count of CD8 ϩ lymphocytes not expressing the CD45 RA marker in the animals that demonstrated CD4 ϩ T cell declines and disease progression, but not in those that did not (Fig. 2) .
We further observed that there was a loss of CD4 ϩ "naïve" CD45RA ϩ cells, concomitantly or slightly following the total CD4 ϩ T lymphocyte decline. In contrast, the percentage of CD8 ϩ CD45RA ϩ naïve cells was preserved and even increased, both during acute and chronic infection.
Plasma viral RNA levels in the SHIV-infected monkeys
Specimens for virus load quantitation were collected at different time points postinoculation. As seen in Fig. 3 , the highest levels of virus replication during primary infection were seen in all animals at 2-4 weeks postinoculation. By 10 weeks, virus replication had decreased dramatically and persisted at levels near the limit of detection for several months. Only one animal (RAQ-5, from Group A) had a high virus load at 14 weeks postinoculation; virus load became undetectable 8 weeks later, after initiation of PMPA therapy. With regards to the effects of PMPA on virus load, our data do not allow us to conclude with certainty what the extent of the effect was. The animals placed on PMPA were all started on the medication after the primary infection phase (Ͼ6 weeks postinoculation), so its effects on viral and immune parameters in the acute phase of infection cannot be evaluated. In the case of RBJ-5, therapy was started at 6 weeks after inoculation, when the virus load had already declined to the limit of detection; in RAQ-5, PMPA was started at 14 weeks after inoculation, and the virus load did decrease from 8.54 log to undetectable within 8 weeks. Finally, in RQI-5, treatment was started at 8 weeks postinoculation, when the virus load was 4.8 log, and discontinued 4 weeks later, with virus load levels that had become and subsequently remained undetectable. So PMPA seemed to help in curtailing viral replication, but the extent of its contribution to the overall viral and immune kinetics of the infection is unclear.
Plasma viral RNA levels during either primary or chronic infection did not differ among the groups with different disease progression patterns.
Evolution of envelope-specific antibody responses in rhesus monkeys infected with SHIV-KB9
We characterized the evolution of virus-specific antibody responses to the HIV-1 envelope, by analyzing longitudinally serum samples from the KB9-infected rhesus monkeys with the different disease patterns. As shown in Fig. 4 , quantitative and qualitative changes in HIV-1 envelope-specific serum antibody were apparent during the first several months postinoculation in all three groups. Serum antibodies directed against HIV-1gp120 were detectable in all animals by 1 month post-FIG. 1. CD4 ϩ T lymphocyte counts in rhesus macaques infected with SHIV-KB9 demonstrating different clinical outcomes: Monkeys that did not demonstrate any CD4 ϩ T lymphocyte count decreases after inoculation (RDO-5, RAP-5), monkeys whose CD4 ϩ T lymphocyte nadir after inoculation was Ͼ50 cells/L and partially recovered their CD4 ϩ T lymphocyte numbers (RHR-5, RQI-5), and monkeys whose CD4 ϩ T lymphocyte nadir after inoculation was Ͻ50 cells/L and which failed to substantially recover their CD4 ϩ T lymphocyte numbers (RBJ-5, RAQ-5).
inoculation. Levels increased subsequently, reaching maximum titers by 2-3 months. The two monkeys of group A only showed a transient and weak response ( Fig. 4A ): one of them (RBJ-5) died at 10 weeks postinoculation; the other (RAQ-5) demonstrated a modest increase in antibody titer up to three times the background levels but lost the antibody by 10 weeks postinoculation and did not develop a response afterward. In the other four animals, once maximum titers were achieved, they were maintained at relatively constant levels for at least 6 months postinfection for both progressors and nonprogressors ( Fig. 4A ). After 6 weeks postinoculation, the two animals from group B reached two-to fourfold higher antibody titers than the two nonprogressors of group C (Fig. 4A ).
Qualitative changes in antibody avidity were also observed during this time (Fig. 4B) . While low avidity index values of about 8-15% were evident at 2 months postin- fection, these gradually increased during the first 10 months, reaching maximum values of 35-45% for both progressors and nonprogressors.
These data demonstrate a gradual maturation of HIV-1 envelope-specific serum antibodies in response to SHIV infection during the first several months postinoculation, characterized by increasing antibody titer and avidity. It appears that virus-specific antibody requires about 8-10 months to fully mature and is independent of clinical course, as evidenced by the similar patterns of antibody maturation in the animals that progressed compared with those that remained asymptomatic.
In contrast, antibodies to tetanus became detectable in most cases after the first dose and reached high titers after the second dose of the vaccine in all but one animal from group A. Antibody avidity to tetanus toxoid reached very high levels (80-90%) in all animals by 1-2 months after the first dose of the vaccine (data not shown).
Cytokine production in response to viral antigens
ELISPOT assays were performed with PBMC stimulated with recombinant antigens, including four SIVmac Gag peptide pools, SIVmac Nef, and HIV MN gp120. In general, the six monkeys displayed broad reactivity to the different viral antigens ( Fig. 5 ). Of note was the fact that the highest frequency of IFN-␥-producing cells was observed in response to Gag antigens, followed by Nef; the lowest reactivity was observed toward gp120, similar to previous observations (Kuroda et al., 1998; Larsson et al., 1999) . The added frequencies of T cells specific to the different antigens were up to 872 per 10 5 PBMC in the monkeys from group A, 2265 in the monkeys from group B, and 1010 in the animals from group C at 2 weeks postinoculation; the respective frequencies at 6 weeks were 420, 1115, and 827, respectively. The range of frequencies of SFC to all six antigens in our animal cohort per 10 5 PBMC was Gag, 0-446; Nef, 0-539; and HIVgp120, 0-824. Thus, the animals with resistance to disease displayed similar responses compared to those with disease; in fact, the highest responses were observed in those animals which exhibited partial CD4 ϩ T cell recovery after an initial phase of decline (group B).
The SIV-specific responses in three of the animals (one of each clinical outcome) were compared at 2, 6, and 12 weeks after inoculation. The responses generally showed a decrease by 12 weeks after infection ( Fig. 5 ).
SIV antigen-specific CD8 T cells were enumerated by tetrameric binding in the Mamu A*-01ϩ animal (RQI-5). The CD8 population (1.05%) bound the MHC A*01-Gag p11 complex; 0.95% of CD8 ϩ T cells produced IFN-␥ at 1 year after infection (data not shown). RQI-5's anti-Gag responses appeared to be directed mainly toward the HLA A*01 restricted epitope, as the percentage of CD8 ϩ T cells reacting was similar when peptide p11c or peptide pool 1 (which includes p11c) were used as sources of antigen, similar to what has been previously observed by Kuroda et al. in 1998 . The ELISPOT assays are likely to be more useful than the tetrameric assays, as they can elicit responses to many peptides and to all possible haplotypes.
Thymic output in the SHIV-infected monkeys
We quantitated thymic output by TREC measurement in the peripheral blood of three of the six SHIV-KB9infected rhesus macaques. The results are shown in Fig.  6 . We observed that all monkeys had TREC levels of 40,000-100,000/10 6 PBMC before infection; these results FIG. 3 . Plasma viral RNA levels in rhesus monkeys infected with SHIV-KB9. Plasma viral RNA levels were measured: (A) during primary viremia, by 6 weeks after inoculation, and (B) at Ͼ10 weeks after SHIV-KB9 inoculation. Infected monkeys were divided into three groups: (A) those with profound CD4 ϩ T lymphocyte decreases and failure to recover, (B) those with higher CD4 ϩ T lymphocyte counts and partial recovery, and (C) those with high CD4 ϩ T lymphocyte counts that did not demonstrate any signs of immunodeficiency. Each symbol represents one animal. Limit of detection was 1000 copies/ml. are comparable with previously published findings for juvenile monkeys (Sodora et al., 2000) . After SHIV-KB9 inoculation we observed different patterns of TREC change, consistent with the clinical outcomes described above (Fig. 6 ): The monkeys with the low CD4 ϩ T cell nadir and rapid disease progression displayed rapid decreases (1 log) as early as 2 weeks postinoculation that were either sustained (RBJ-5) or showed small fluctuations with an overall downward trend (RAQ-5). In contrast, the animal without CD4 ϩ depletion showed persistence in TREC levels throughout the course of the infection. A transient decline 2 weeks after inoculation was followed by rapid return to preinoculation levels; this could be due to a concurrent increase in CD8 ϩ CD45 RAϪ cells. Even though both thymic cell generation and peripheral cell turnover affect TREC levels, these results confirm previous histological observations of marked thymic disruption in SHIV-infected macaques (Li et al., 1995) and suggest that thymic dysfunction is an important determinant of disease progression in this SHIV model.
DISCUSSION
The patterns of disease development and progression after SHIV-KB9 intravenous inoculation of rhesus macaques have been previously characterized (Reimann et al., 1996 (Reimann et al., , 1999 . We observed yet another pattern that has not been previously described after intravenous inoculation of rhesus monkeys with SHIV KB9: two of six animals in our cohort did not display any CD4 ϩ T cell depletion or clinical signs of immunodeficiency, despite their having been infected with the same viral stock and viral dose and by the same route as the other animals.
This intriguing observation led to questions regarding determinants of pathology and clinical outcome after inoculation of different animals with the same pathogenic clone. It might have been expected that the viral clone would cause a more uniform pattern of clinical and immunological decline. However this is not the case, as we and others have observed. In vivo evolution of the virus leading to loss of its pathogenicity very early in infection versus host-immune or genetic factors offer Viral load has been shown to influence disease progression in humans infected with HIV (Mellors et al., 1996) , as well as in macaques infected with SIV or SHIV (Chakrabarti et al., 1994; Reimann et al., 1996; Shibata et al., 1997; Kozyrev et al., 2001) . In fact, the highest levels of SHIV-induced primary viremia were observed after infection with 89.6P, the strain from which SHIV-KB9 was cloned (Reimann et al., 1996) ; this virus has the highest potential for causing acute and rapid CD4 ϩ T cell loss compared to all previously developed chimeric strains. These observations support the idea that virus replication does influence disease progression in these ani-mals; however, it must not be the only parameter, since in our animals very different clinical outcomes were seen, despite comparable levels of virus load during acute infection and similar kinetics of viral replication during established infection. Indeed, in a recent study, pathogenicity of SHIV-89.6P molecular clones did not seem to correlate with initial viral replication (Kozyrev et al., 2001) . Dual-tropic viruses are not homogeneous in their coreceptor usage, but comprise a continuum of variants that use CXCR4 and CCR5 to different degrees. It has been shown that coreceptor utilization plays a critical role in viral pathogenesis, with differential targeting of lymphocyte populations during acute infection (Harouse et al., 1999) . It is possible that KB9 might have shifted in its coreceptor usage, allowing for different pathology in the animals. We attempted to detect such differential evolution of the virus in the animals with the distinct clinical outcomes; however, we found that all animals had retained the original V3-V5, as well as GP41 and nef sequences in their predominant circulating virus (data not shown). It is possible that critical sequence changes might have occurred in other regions; such studies are currently in progress in our laboratory. However such mutations would have had to occur very rapidly after infection, which might have been difficult with a monoclonal virus. We therefore hypothesized that host factors, whether genetic (chemokine receptors) or immunologic, must be more important in determining initial disease progression patterns.
An explanation for the rapid CD4 ϩ T cell decline in the animals might be the ability of the virus to disrupt the thymus (Li et al., 1995; Ilda et al., 2000) . It has been previously shown in histopathologic studies that the SHIV 89.6P strain is found in the thymus very early after inoculation, disrupting thymic architecture, and a large number of apoptotic cells was observed in the thymus as early as 14 days postinfection with SHIV 89.6P (Ilda et al., 2000) . We examined the thymic output in our cohort of infected animals by TREC quantitation. Our data show two distinct patterns of thymic output kinetics during the course of infection: The animals in which the CD4 ϩ T cells decline displayed a decrease of TREC as soon as 2 weeks after inoculation, whereas the animals with preserved CD4 ϩ T cell counts sustained their preinfection levels of TREC. To our knowledge, this is the first report of thymic output using TREC assays in retrovirusinfected monkeys. It should be kept in mind that TREC measurements are influenced not only by new thymic lymphocyte generation, but also by peripheral T cell proliferation; thus, cell conversion from naïve to "activated" phenotype as a result of antigenic stimulation will also decrease TREC levels and may be a contributing factor to the pattern of TREC decline we observed in the progressing animals. We further observed that there were profound decreases of CD4 ϩ CD45RA ϩ T lymphocytes as early as 2-4 weeks postinoculation in the progressing animals, but not in the nonprogressing ones; however, CD8 ϩ CD45RA ϩ T lymphocytes did not exhibit a corresponding decrease casting doubt on the utility of this marker as an index of thymic output (Champagne et al., 2001) .
We attempted to further define the immunologic response to the SHIV-KB9 clone, by antibody development, T cell cytokine secretion, and lymphocyte surface marker expression in the animals with the different disease patterns.
We used antibody responses to recombinant HIV-1 MN gp120 to study the nature of virus-specific antibody responses to SHIV infection. Our findings confirmed previous observations (Cole et al., 1998 ) of a lengthy matura-tion of envelope-specific antibodies in rhesus macaques, and of similar patterns of antibody maturation in progressing versus nonprogressing animals. The exception to this was the two animals with the rapid, profound, and sustained CD4 ϩ T cell decreases, which did not mount an adequate antibody response, similar to what was previously observed by Reiman et al. in 1999 , Lu et al. in 1998 , and Ilda et al. in 2000 HIV-1 ELISA, agglutination, or Western blot assays. Of interest is the fact that animals from group B achieved higher antibody titers than those of group C. We found that antibody avidity did not reach maximum values (which were of moderate degree-less than 50%), until 10 months postinoculation, whereas the antibody titer achieved high levels much earlier (by 3-4 months in our study), thus preceding antibody maturation by 6-7 months. The lack of correlation of antibody titer and avidity with clinical outcome suggest that antibody production is only one of several immune variables associated with protection. Interestingly, antibody responses to tetanus toxoid were produced in high titer and avidity in all animals; they were maintained in all but the animal with the most profound immunodeficiency, suggesting that the loss of antibody may be a direct consequence of the marked CD4 ϩ T cell defect.
Cellular immune responses were studied by comparing activation levels of different T cell subsets at various stages postinoculation. An interesting pattern was observed, according to which, the animals with a lack of CD4 ϩ T cell depletion showed the least activation, as measured by expression of HLA-DR and CD69 and lack of expression of CD45 RA on CD8 ϩ T cells. The progressing animals with the partial CD4 ϩ cell rebound displayed much more pronounced CD8 ϩ T cell activation by all markers. These increases parallel the increases in the absolute number of CD8 ϩ T cells observed 5-15 weeks after infection.
The above observations support previously reported findings, that a "wave" of lymphocyte activation occurs soon after primary SHIV infection (Wallace et al., 1999) . This activation may correlate with virus replication and direct and indirect CD4 ϩ T cell killing or with antiviral cytotoxic T lymphocyte responses. When studying specific cellular immune responses by ELISPOT, we observed that the number of cells producing interferon-␥ was highest during the acute phase (2 weeks postinoculation) in all animals tested and generally subsided by 12 weeks postinoculation. We observed that the animals with CD4 ϩ T cell loss and partial rebound had higher responses in the acute infection stage than those with CD4 ϩ T cell decline. These data suggest that additional factors, possibly related to differential viral entry within different immune cell types, might be primarily responsible for protection against disease in these latter animals.
In conclusion, SHIV-KB9 infection can be nonpatho-genic in the rhesus macaque; divergent clinical outcomes seem to be related to several differences in host response to the infection. Even though no differences were observed in the viral load kinetics, differences in immune activation and response patterns of CD8 ϩ and B lymphocytes and in thymic output were observed in the animals that progressed, as compared with those that did not. Ongoing studies on the viral genotype and on coreceptor utilization may shed further light on viral and host determinants of nonpathogenic SHIV infection. Our findings have implications for the use of this virus in vaccine studies.
MATERIALS AND METHODS
Animals
The study group comprised six juvenile rhesus macaques (Macacca mulatta), bred at the Yerkes Regional Primate Center, Atlanta, GA (RDO-5, RAP-5, RAQ-5, RHR-5, RBJ-5, RQI-5). The animals were housed and maintained according to the guidelines of the Committee for the Care and Maintenance of Primates of Emory University and the "Guide for the Care and Use of Laboratory Animals" (National Research Council, National Academic Press, Washington, DC, 1996) . Animals were sedated with ketamine before venipuncture or vaccinations and were examined clinically while under anesthesia. All animals were inoculated intravenously with SHIV-KB9 grown in CEMx174 cells. The animals had previously been immunized with three doses, at 2-month intervals, of tetanus toxoid (0.5 ml im). Tenofovir (PMPA) is a nonnucleoside reverse transcriptase inhibitor that was used as antiviral therapy in some animals, as its once daily dosing (20 mg/kg) allows ease of administration (kindly provided by N. Bischofberber, Gilead Sciences, Foster City, CA).
Virus
The parental virus, SHIV 89.6P, has been previously described as a pathogenic virus inducing rapid CD4 ϩ cell depletion and AIDS-like illness in rhesus monkeys (Karlsson et al., 1997) . Briefly, KB9 contains the tat, rev, vpu, and env genes of HIV-1 in an SIV mac 239 (nef open) background. The env gene is derived from a cytopathic, primary HIV-1 isolate, 89.6, which is tropic in vitro for both macrophages and T cells. The viral genome is contained on two plasmids and virus is produced by ligation of the SphI-digested 5Ј and 3Ј proviral halves, followed by transfection of CEMx174 cells, as described previously (Reimann et al., 1996) . The infection of juvenile rhesus monkeys (M. mulatta) with SHIV 89.6, and four serial in vivo passages by intravenous blood inoculation, led to the generation of a molecular clone, KB9, which, after ligation to the SIV mac 239 5Ј proviral half, induced rapid decreases of CD4 ϩ lymphocytes in all three mon-keys initially inoculated (Reimann et al., 1996) . The increased virulence of this virus was attributed to differences in envelope ectodomain sequences, increasing membrane fusogenicity (Etemad-Moghadam et al., 2000 . This chimeric virus was obtained from Dr. K. Reimann, Beth Israel Deaconess Medical Center, Boston, MA. The virus stock was propagated on rhesus PBMC and the titer determined by titration in CEMx174 cells. Monkeys infected with this virus received 10-1000 animal infectious doses, as previously described (Karlsson et al., 1997; Reimann et al., 2001) .
Quantitation of plasma viral RNA
A QC-PCR method developed for SIVmac was used, as previously described (Zhou et al., 1999) . Primers used in this assay hybridized with SIV Gag. Briefly, plasma RNA was extracted and then reverse transcribed in the presence of 500 copies of competitor RNA. These reaction products were amplified by PCR and separated on an agarose gel. The viral RNA yielded a 336-bp band, and the control yielded a 253-bp band. Viral RNA levels were calculated from the dilution of a sample that produced a visual signal equivalent to the internal control.
Staining and phenotypic analysis of lymphocyte subsets and p11c-specific CD8 ϩ T cells
The monoclonal antibodies (mAbs) used for surface staining included the following directly conjugated to FITC, PE, or PerCP: CD3 (clone SP34, Pharmingen, San Diego, CA), CD4, CD8, CD20, CD69, HLA-DR (Becton-Dickinson, San Jose, CA), CD45RA (RD1-2H4); and PEcoupled tetrameric Mamu-A*01/p11C. Immunophenotyping was done on lysates of freshly drawn whole blood. Briefly, 100 l volumes of whole blood were aliquoted into 12 ϫ 75 mm polystyrene tubes and incubated with directly conjugated surface-staining antibodies for 30 min at room temperature. Red blood cells were lysed with 2 ml FACSLyse solution (BDIS, San Jose, CA) for 10 min at room temperature and washed twice with wash medium (phosphate-buffered saline (PBS) containing 2% fetal calf serum). Stained cells were fixed in 1% paraformaldehyde and kept overnight at 4°C prior to acquisition and analysis on a FACScan (BDIS). Isotype controls were used to set negative gates. Relative percentages and absolute numbers of cells in each subset were calculated using CellQuest Software (BDIS) and absolute lymphocyte counts were obtained from an automated cell counter Sysmex K1000 with a manual differential.
Measurement of viral envelope glycoprotein-specific antibody by ELISA
Serum samples from SHIV-KB9-infected macaques were analyzed for their reactivity to recombinant HIV envelope glycoprotein gp120 MN (National Institutes of Health, Bethesda, MD). MN is a monocytotropic labora-tory HIV-1 strain. ELISA was performed in microtiter plates coated overnight with recombinant gp120 at 0.5 g/ml PBS. After blocking the wells with 3% nonfat dry milk in PBS (BLOTTO), diluted monkey serum was added to each well and incubated for 2 h at 37°C. Following washing with PBS-0.05% Tween 20, the wells were incubated with mouse anti-human IgG (Sigma) coupled to horseradish peroxidase, for 1 h at 37°C. The wells were again washed and incubated with ortho-phenyl-diamine (OPD) substrate, and the optical density (OD) was measured at 490 nm using an automated plate reader (Dynatech) . All experiments were run in duplicate. Serial twofold dilutions of a pool of reactive sera were run to construct a standard curve and titers of individual sera are reported as titers off the linear range of the curve. Several different dilutions of sera were run to ensure that the absorbance value was within this linear range.
Measurement of viral envelope glycoprotein-specific antibody avidity
The avidity of ELISA antibody against gp120 was measured by titration of sera in the presence or absence of 2 M sodium thiocyanate (SCN). The avidity index of serum antibodies against HIV gp120 was calculated by measuring the resistance of the serum antibody-envelope glycoprotein complexes in the ELISA assay to 2 M SCN, as previously described (Cole et al., 1998) . Briefly, recombinant viral gp120 was coated onto microtiter plates as described above for the ELISA. All test sera were again diluted in BLOTTO to produce an OD at 490 nm of about 1.0 to 1.5 and were plated in two sets of duplicate wells. Following the serum incubation, duplicate wells were treated in parallel with either PBS alone or a solution of 2 M SCN in PBS (15 min at room temperature). Following washing with PBS-0.05% Tween 20, the wells were incubated with peroxidase-conjugated anti-human IgG and developed as described above in the ELISA procedure. The avidity index was calculated from the ratio of absorbance value obtained with SCN treatment to that observed with PBS treatment multiplied by 100%.
Measurement of antibodies and antibody avidity to tetanus toxoid
A specific ELISA assay for tetanus antibodies has been established in our laboratory. Tetanus toxoid was purchased from Connaught Laboratories and used at a dilution of 1:400 in carbonate buffer. Sera were diluted at 1:1000 and the assays were performed as described above.
ELISPOT assays
Elispot assays were performed using a modification of recently described techniques (Haslett et al., 2000; Larsson et al., 1999) . Briefly, cryopreserved peripheral blood mononuclear cells (PBMC) were incubated at 3 ϫ 10 5 cells/well with the antigen of interest in RPMI-1640 culture medium supplemented with 10% fetal calf serum and penicillin (10 IU/ml)-streptomycin (10 mg/ml) onto 96well plates (Millititer, Millipore, Bedford, MA). The plates had been precoated overnight with anti-interferon-␥ monoclonal antibody (5 g/ml, Pharmingen) and blocked with culture media containing 10% fetal calf serum. The incubation proceeded for 24-36 h at 37°C in a 5% CO 2 incubator. The antigens of interest included four SIV gag p55 peptide pools encompassing the whole gag region (kindly provided by Dr. Harriet Robinson, Yerkes Primate Research Center, Atlanta, GA), recombinant SIV nef, HIV MN gp120 (NIH AIDS Research Reagent Program), or staphylococcal enterotoxin B (SEB, Toxin Technologies, Sarasota, FL, 10 ng/ml). All cultures were performed in duplicate. The plates were subsequently washed four times with PBS-0.05% Tween-20 (Sigma, St. Louis, MI) and a secondary biotin-labeled anti-interferon-␥ monoclonal antibody was added for 2 h at 37°C (clone 7-B6-1, 1 g/ml, MabTech, Stockholm, Sweden). The wells were washed and avidin-peroxidase complex was added (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) for 1 h at room temperature. After washing, substrate was added (diaminobenzidine (DAB), Research Genetics, Huntsville, AL) and then finally rinsed out with water. Resulting brown spots were counted with an ELISPOT plate reader (Immunospot Analyzer, CTL, OH), each spot representing IFN-␥ production by a single cell. Data were expressed as the number of spot-forming cells (SFC) per 10 5 input cells after subtraction of the background and of the responses observed to the respective antigens at baseline (time of inoculation), to exclude cross-reacting activity and antigen impurity.
Thymic output assays
Thymic output was measured by quantitation of T cell receptor (TCR) rearrangement circles (TREC), produced during TCR rearrangement in the developing thymocytes. Signal-joint TREC primers for human developed by Douek et al. (Douek et al., 1998; McFarland et al., 2000) were employed to amplify the corresponding DNA sequences of the rhesus macaques. Based upon the rhesus macaque sequences, we developed a real-time PCR for the TREC assay in macaques using the TaqMan system to quantitate TREC in peripheral blood lymphocytes. The design of TaqMan probes, combined with the 5Ј to 3Ј nuclease activity of AmpliTaq Gold polymerase, allows direct detection of PCR product by the release of a fluorescent reporter during the PCR on the ABI Prism 7700 Sequence Detector. The TaqMan probe consists of an oligonucleotide with a 5Ј reporter dye and a downstream 3Ј quencher dye. Each of the reporters is quenched by 6-carboxy-tetramethylrhodamine (TAMRA). When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. During PCR, forward and reverse primers hybridize to a specific sequence of the target DNA. The TaqMan probe hybridizes to a target sequence within the PCR product. The AmpliTaq Gold enzyme cleaves the TaqMan probe with its 5Ј to 3Ј nuclease activity. The reporter dye and quencher dye are separated upon cleavage, thus resulting in increased fluorescence of the reporter. This process occurs in every cycle and does not interfere with the exponential accumulation of the product. The separation of the reporter dye from the quencher dye results in increase in fluorescence for the reporter. The increase in fluorescence (kinetics) is measured and is a direct consequence of target amplification during PCR. The designed primers employed for the TREC assay were MTRF, MTRH, and fluorescent FAM-labeled probe MTRP (attached). Every real-time PCR was run in a 50-l reaction containing 10ϫ buffer, 5 mM MgCl 2 , 0.25 mM of each dNTPs and 500 mM of each primers and probe. After 2 min of incubation at 50°C, and 10 min at 95°C for denaturation, the samples were subjected to 60 cycles of PCR, with each cycle consisting of 30 s at 95°C and 30 s at 60°C. All the samples, as well as the control standard of known amount of DNA, were run either in duplicate or in triplicate.
The control standard DNA was the amplified monkey TREC sequence with primers by Douek et al. in 1998 cloned in pCRII vector. After miniprep isolation, the plasmid standard DNA was quantified by spectrophotometer and the number of copies per microliter calculated. The determination of TREC copy number in the samples was done by comparison of the number of PCR cycles at which fluorescence was detected to the number of PCR cycles.
